Nuvectis Pharma said China approved Ciprocopan for paroxysmal nocturnal hemoglobinuria patients not previously treated with complement inhibitors. The clearance

Nuvectis Pharma said China approved Ciprocopan for paroxysmal nocturnal hemoglobinuria patients not previously treated with complement inhibitors. The clearance gives the drug access to a major market and advances the company’s global expansion strategy.